ASIT biotech announces the grant of a European patent on the active ingredients used in the ASIT+™ allergy immunotherapy product candidates

Brussels, Belgium, October 17, 2017, 6:30 pm (CEST) – ASIT biotech (Euronext: ASIT – BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announces the positive decision of the European Patent Office to grant a patent covering the active ingredients used in the ASIT+™ allergy immunotherapy products candidates for pollen, mite and food allergies.

The grant will be effective from November 1, 2017 until June 28, 2027 with a possible extension of 5 years via a supplementary protection certificate. The corresponding patents are already granted in China, Japan and India. Patent prosecutions for the grants of the corresponding patents in the USA and Brazil are ongoing.

Thierry LEGON, CEO of ASIT biotech, comments: “The grant of this patent in Europe is a major milestone in the protection of our assets as well as a recognition that our products are unique and innovative. Europe is currently the biggest market of allergy immunotherapy products in the world. Therefore, the long-term protection conferred by this patent in Europe is of high strategic importance.”

 

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection.

This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market.

The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies. ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at: www.asitbiotech.com.

You Might Also Like